Palisade Bio (PALI) Stock Price, News & Analysis

Company Overview

Palisade Bio, Inc. is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations.

Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events.

Key Stats

• Today's Range: $2.00 to $2.12
• 50-Day Range: $1.89 to $2.24
• 52-Week Range: $0.53 to $2.86
• Volume: 1.76 million shs
• Average Volume: 1.53 million shs
• Market Capitalization: $364.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Palisade Bio Stock Analysis - MarketRank™

Palisade Bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 420th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Palisade Bio has a consensus price target of $9.00, representing about 330.6% upside from its current price of $2.09.

Amount of Analyst Coverage

Palisade Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Palisade Bio are expected to decrease in the coming year, from ($0.23) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palisade Bio is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palisade Bio is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palisade Bio has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.17% of the float of Palisade Bio has been sold short.

Short Interest Ratio / Days to Cover

Palisade Bio has a short interest ratio ("days to cover") of 22.04, which indicates bearish sentiment.

Change versus previous month

Short interest in Palisade Bio has recently decreased by 0.92%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palisade Bio does not currently pay a dividend.

Dividend Growth

Palisade Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.19

News Sentiment

Palisade Bio has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Palisade Bio this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

MarketBeat Follows

7 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Palisade Bio insiders have sold 64.02% more of their company's stock than they have bought. Specifically, they have bought $250,100.00 in company stock and sold $410,226.00 in company stock.

Percentage Held by Insiders

0.07% of the stock of Palisade Bio is held by insiders.

Percentage Held by Institutions

11.79% of the stock of Palisade Bio is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/06/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/16/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PALI
• CIK: 1357459
• Web: www.palisadebio.com
• Phone: (858) 704-4900
• Fax: N/A
• Employees: 10
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Palisade Bio: $9.00
• High Price Target: $25.00
• Low Price Target: $2.00
• Potential Upside/Downside: +330.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.78 million
• Net Margins: N/A
• Pretax Margin: -6,388.20%
• Return on Equity: -33.47%
• Return on Assets: -31.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.26
• Quick Ratio: 24.26

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 1,456.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.70 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 174,270,000
• Free Float: 174,149,000
• Market Cap: $364.22 million
• Optionable: Not Optionable
• Beta: 1.53